Abstract
Chronic hepatitis B infection (CHB) is a global health disaster with over 1 million people dying annually from this infection worldwide. A large burden of morbidity and mortality is in the WHO-African Region (WHO-AFRO) however here <5% of people are diagnosed and 0.2% on treatment. Community understanding of HBV is often poor and people living with HBV (PLWHB) can experience stigma and discrimination. However there has been little documentation on the impact of an HBV diagnosis on the lives of PLWHB. We explore the experience of PLWHB in Kilifi, Kenya, including their understanding of the disease, how their diagnosis has changed their lives and what barriers they have experienced when accessing care. We show overall understanding of HBV in this group is good, with most participants knowing transmission routes and available treatment. In the general community however, HBV understanding is poor - there is no local name for the infection other than the symptoms it causes such as swollen tummy and yellow eyes. Many participants felt shocked at their initial diagnosis and had mixed reactions from friends and family. Costs of transport and concerns about lost employment were seen as the biggest barrier to care with many people advocating for decentralised clinics. Stigma was also raised with people feeling isolated, rejected and discriminated against. There was also discomfort around the current integration of HBV and HIV services at KCRH, with concerns over increased stigma, longer waiting times and preferential treatment being given to those living with HIV.
Community education, provision of wider testing and advocacy by well-respected community members were mentioned as key methods to reduce HBV transmission. Decentralisation of clinics may improve access to care; however the patient voice must be considered when planning future interventions to ensure these are acceptable and accessible to the community.
Competing Interest Statement
PCM has previously received funding from GSK for a PhD student in her group. This has had no influence over the planning or undertaking of the study, the writing of the manuscript or decision to publish.
Funding Statement
This project is funded by the Wellcome Trust (grant 225485/Z/22/Z) and the John Fell Fund, University of Oxford (ref: 0012112).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the KEMRI Scientific Ethics Review Unit (SERU): KEMRI/SERU/CGMRC-C/075/3416 VER. 1.8 25/05/2020)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
